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Background: Along with de novo resistance, continued exposure to trastuzumab, an anti-human epidermal
growth factor receptor 2 (HER2/neu) antibody, can lead to acquired resistance. In this study, we characterize a
new anti-HER2/neu antibody resistant and metastatic mouse breast carcinoma cell line, TUBO-P2J. This cell line
was developed during in vivo experiments using the antibody sensitive and non-metastatic tumor line TUBO. In
addition, TUBO-P2J was used to establish an intratumoral HER2 heterogenous animal tumor model to evaluate
the therapeutic effects of anti-HER2/neu antibody.
Methods: After establishing the cell line, TUBO-P2J was characterized regarding its susceptibility to anti-neu
antibody and chemotherapeutics, as well as its metastatic potential in vitro and in vivo. In addition, expression
profiles of metastasis related genes were also evaluated. A clinically relevant intratumoral HER2 heterogenous
tumor model was established by inoculating mice with tumor cells consisting of TUBO and TUBO-P2J at a
ratio of 1,000:1 or 10,000:1. Tumor growth and mouse survival were used to evaluate the therapeutic effects
of anti-neu antibody.
Results: The TUBO-P2J cell line is a HER2/neu negative and highly metastatic variant of TUBO. This cell line was
resistant to anti-neu antibody therapy, and when inoculated subcutaneously, metastasized to the lungs within
14 days. Compared to the parental TUBO cell line, TUBO-P2J displayed an epithelial-mesenchymal transition
(EMT) related gene expression profile including: the loss of E-cadherin, and increased Vimentin, Snail, and Twist1
expression. In addition, TUBO-P2J exhibited increased invasion and migration activity, and was resistant to
chemotherapy drugs. Finally, mixed tumor implantations experiments revealed that an increased percentage
of TUBO-P2J rendered tumors less responsive to anti-neu antibody therapy.
Conclusion: This study describes a novel model of intratumoral heterogenous metastatic breast cancer in
immune competent mice that can be used to develop novel or combined immunotherapies to overcome
antibody resistance.
Keywords: Breast cancer, Anti-HER2/neu antibody, Antibody resistance, Spontaneous metastasis, Epithelial
mesenchymal transition, Intratumoral heterogeneity, Animal model* Correspondence: yxfu@bsd.uchicago.edu; micpsg@inje.ac.kr
†Equal contributors
9Departmentof Pathology and Committee on Immunology, University of
Chicago, 924 E. 57thStreet, BSLC R102, Chicago,
IL 60637, USA
1Departmentof Microbiology and Immunology, INJE University College of
Medicine, 633-165 GaegumDong, Busanjin Gu, Busan 614-735, Republic of
Korea
Full list of author information is available at the end of the article
© 2014 Song et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Song et al. BMC Cancer 2014, 14:647 Page 2 of 12
http://www.biomedcentral.com/1471-2407/14/647Background
Gene amplification and/or overexpression of the human
epidermal growth factor receptor 2 (HER2, ErbB-2) have
been identified in 20-25% of breast cancers and are asso-
ciated with poor prognosis [1]. Trastuzumab (herceptin)
is a humanized, recombinant monoclonal antibody that
binds to the extracellular, juxtamembrane domain of
HER2, and is standard care for patients whose breast
cancer cells show strong immunohistochemical staining
for HER2 or moderate immunohistochemical staining
with HER2/neu gene amplification [2]. Trastuzumab
therapy has improved response rates, time to relapse
and overall survival in woman with HER2-positive
metastatic breast cancer [1,3]. Despite the clinical bene-
fit resulting from trastuzumab administration, primary
and acquired clinical resistance has been increasingly
reported. To overcome resistance, various efforts in-
cluding the recognition of primary and acquired drug
resistance, studies for the molecular mechanisms of re-
sistance, and developing new drugs and strategies were
conducted; however, new approaches are still required.
For some tumors, the epithelial-mesenchymal transition
is considered the first step of the metastatic process.
Metastatic breast cancers likely evolve from less aggressive
epithelial-like breast tumors through reactivation of em-
bryonic signaling pathways and programs like epithelial-
mesenchymal transition (EMT) [4]. EMT can be initiated
by a diverse set of stimuli including growth factor signal-
ing, tumor-stromal cell interactions and hypoxia [5], but
immune responses can also induce EMT through immu-
noediting [6]. In addition, the EMT does not have to be
induced in every cell for metastases to arise. Human
primary tumors consist of heterogeneous populations of
cells that are phenotypically, functionally and genetically
diverse [7]. Even though reports for intratumoral HER2
heterogeneity are increasing, there are no valuable pre-
clinical animal models to test whether trastuzumab or
HER2 targeted treatments are effective or to develop new
treatment strategies.
Recent studies have demonstrated that anti-neu ther-
apy not only directly suppress neu-positive tumors, but
also triggers host immune responses for tumor regres-
sion [8,9]. This suggests that strategies aimed at increas-
ing the immune response generated by anti-neu therapy
may also limit acquired resistance and reduce metastatic
burden. Thus, developing models to study immune acti-
vation in the context of neu resistant tumors is of great
importance. In this study, we employ a novel metastatic
breast cancer tumor model, TUBO-P2J, to discover mecha-
nisms promoting metastatic progression in breast cancer,
and susceptibility to chemotherapeutics and anti-neu ther-
apy. Furthermore, using this cell line we further explored
how intatumoral HER2 heterogenity affected resistance to
anti-HER2/neu therapy.Methods
Mice
Female BALB/c mice were purchased from Orient bio
(Taejun, Korea). All mice used in this study were 6–16
weeks of age in accordance to the animal experimental
guidelines set by the Institutional Animal Care and
Use Committee (IACUC) at the INJE University
College of Medicine. This study was approved by the
INJE University College of Medicine IACUC (protocol
Number 2011-043).
Cell line and reagents
TUBO was cloned from a spontaneous mammary tumor
in a BALB Neu Tg mouse [10]. TUBO cells were cultured
in 5% CO2, and maintained in vitro in DMEM supple-
mented with 10% heat-inactivated fetal bovine serum (FBS)
(Sigma), 10% NCTC 109 medium, 2 mmol/L L-glutamine,
0.1 mmol/L MEM nonessential amino acids, 100 units/mL
penicillin, and 100 μg/mL streptomycin. The anti-neu
monoclonal antibody 7.16.4 was produced in house.
MMP9 specific inhibitor (CAS 1177749-58-4, IC50 for
MMP9 = 5 nM, IC50 for MMP1 = 1.05 μM) was pur-
chased from SantaCruz.
Isolation of metastatic tumor cells
Metastatic TUBO variant cell (TUBO-P2J) was isolated
from metastatic lung nodules by digestion with 1.5 mg/
mL collagenase and 100 ug/mL DNase for 20 minutes at
37°C and then gently pipetted in the presence of 0.01 M
EDTA (ethylene diaminetetraacetic acid) for 1 minute.
Single-cell suspensions were cultured with the same
media used for TUBO cells supplemented with G418
(500 μg/ml).
Migration and invasion assays
The migration potential of TUBO and TUBO-P2J was
evaluated with scratch wound and trans-well migration
assays. Invasion assays were conducted with matrigel
coated trans-well plates. For scratch wound assays, tumor
cells were inoculated into a 6-well plate and incubated until
cells were approximately 80% confluent. “Wounded” mono-
layers were created by scraping the bottom of the wells with
a sterile pipette tip. After washing twice with PBS, cells
were incubated for additional 3 days. Cell migration into
the “wound” was determined by microscopic observation.
Trans-well experiments were performed using 8.0-um pore
size 24-well insert systems (BD Falcon) with 2 mg/ml of
Matrigel coating (invasion) or not (migration). 5 × 104 cells
(migration) or 5 × 105 cells (invasion) were added to the
upper chamber and incubated for 4 hours (migration) or
72 hours (invasion). After incubation, the upper surface of
the membrane was wiped with a cotton-tipped applicator
to remove residual cells. Cells in the bottom compartment
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selected fields at × 400 magnifications were counted.
Zymography
For analysis of proteolytic capacity, culture supernatants
of TUBO and TUBO-P2J cells were concentrated with
Aquacide (Sigma) and diluted to a final protein concen-
tration of 1 mg/ml, and then mixed with sample buffer
containing sodium dodecyl sulfate (SDS), glycerol, and
bromophenol blue. Equal amounts of each sample were
separated on an SDS-polyacrylamide gel (7.5%) contain-
ing 0.8 mg/ml gelatin (Merck, Darmstadt, Germany).
After electrophoresis, the gels were washed twice with
2.5% Triton × 100 for 30 min to remove any remaining
SDS, then washed twice with distilled water and were
finally equilibrated with incubation buffer (100 mM
Tris/HCl, 30 mM CaCl2, 0.01% NaN3). The gel was then
incubated in incubation buffer for 20 hours at 37°C.
Staining of protein was performed with Coomassie BlueTable 1 Information on primers used in RT-PCRs



























GAPDH NM_008084 TTCACCACCATGGAGAAGGCsolution (10 ml of acetic acid, 40 ml of distilled water,
50 ml of methanol, 0.25% Coomassie Blue G250 [SERVA,
Heidelberg, Germany]) for 40 min. De-staining was per-
formed in methanol/acetic acid/distilled water (25:7:68, by
vol.). After staining, white bands on blue gels indicate en-
zyme species.RT-PCR
Total RNA extracted from cultured cells was used as a
template for reverse transcriptase reaction. Aliquots of
cDNA were amplified using the primers (Table 1). After
an initial denaturation at 94°C for 5 min, the following
was performed: 30 cycles of denaturation at 94°C for
30 seconds, annealing at 55 -60°C for 30 seconds, and
extension at 72°C for 60 seconds. The reaction products
were analyzed in 1.5% agarose gels. The amplified DNA
fragments were cloned and sequenced in order to con-
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Quantitative real-time reverse transcription-PCR (qRT-
PCR) was performed with fluorescent SYBR Green using
an ABI Step One Plus system (Applied Biosystems) fol-
lowing the manufacturer’s instructions. The standard
glyceraldehydes-3-phosphate dehydrogenase (GAPDH)
was used to normalize variations in input cDNA. Quanti-
tative PCR reactions were performed in triplicate.
Flow cytometry
To determine the surface expression of rat neu, cells
were harvested and washed with phosphate buffered sa-
line (PBS). The cells were then suspended with 0.5% bo-
vine serum albumin (BSA) in PBS and then each labeled
with 1ug/ml of anti-neu antibody. After incubation for
30 min at 4°C, data acquisition and flow cytometry ana-
lysis were performed with FACS Calibur using the Cell
Quest software (BD Biosciences).
Western blot
Cell lysate (30ug/lane) was electrophoresed on poly-
acrylamide-SDS gel and then transferred to polyvinylidene
fluoride membrane. Immunoblotting was performed by
various primary antibodies. E-cadherin, Vimentin and Snail
1 antibodies were obtained from Cell Signaling Technology
(Beverly, MA). Actin antibody was obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). Twist antibody was
purchased from Abcam (Cambridge, MA). Western blots
are representative of three independent experiments.
In vitro proliferation assay
Cell viability was measured using the Cell Proliferation
Reagent WST-1 (Roche Diagnostics, IN, USA) according
to the manufacturer’s protocol. 1-2 × 103 cells of TUBO
or TUBO-P2J cells were seeded in 96-well plates and in-
cubated with various concentrations of antibody or
chemo drugs for 72 hours. WST-1 reagent was added
and incubated with the cells for 1 hour. The absorbance
was determined at 450 nm with an ELISA plate reader.
Tumor inoculation and antibody treatments
TUBO or TUBO-P2J cells were detached from culture
flasks by incubating for 3–5 minutes in 1 × Trypsin EDTA
(Mediatech Inc., Manassas, VA). Cells were washed 2–3
times in 1× PBS and counted by trypan blue exclusion. 2-
5 × 105 TUBO, TUBO-P2J or a mixture of the two cells was
injected subcutaneously in the back of 6 to 8-week-old mice
anesthetized with a mixture of ketamine (90 mg/kg) and
xylazine (10 mg/kg). Tumor volumes were measured along
three orthogonal axes (x, y, and z) and calculated as tumor
volume = (xyz)/2.
Tumor bearing mice were treated with 2 or 4 times
with intraperitoneal injections of 100 to 200 μg of anti-
neu antibody (clone 7.16.4).Immunohistochemistry
Tumor tissues were fixed in 4% paraformaldehyde and
then were embedded in paraffin blocks. Tissue sections
from a paraffin block (4 μm thick) were incubated in
tris-EDTA buffer (pH 8.0) and heated to 99°C for
30 min. After the endogenous peroxidase activity was
quenched with 3% hydrogen peroxide, the sections
were treated with UV inhibitor (Ventana, CA, USA).
The sections were incubated with rabbit anti-rNeu
antibody (Cell Signaling) and HRP-conjugated goat
anti-rabbit IgG (Jackson ImmunoResearch Lab. PA,
USA). Finally, counterstaining was performed with
Mayer’s hematoxylin. IHC grading was done as follow-
ing ASCO Clinical Practice Guideline [2].
Statistical analysis
Differences between groups were analyzed using an un-
paired t test. Error bars represent ± SD. All statistical
analyses were conducted using Graph-Pad Prism Version
4.0 (GraphPad Software). Unless specified, statistically sig-
nificant differences of P <0.05, 0.01, and 0.001 are noted
with *, **, ***, respectively. Differences that were not statisti-
cally significant were left unnoted.
Results
TUBO-P2J cell line is a HER2/neu loss variant resistant to
anti-neu antibody and chemotherateutics
Spontaneous metastases have not been reported in
previous studies using subcutaneous implantation of
TUBO. However, during TUBO transplant experi-
ments in NeuTg F1mice (FVB/N-Tg/MMTV-neu ×
BALB/c), a few anti-neu antibody treated mice became
very sick with cachexia. Autopsies were conducted to
evaluate the cause of the sickness and revealed that the
lymph nodes and spleens of these mice were enlarged
and a numbers of nodules were detected in the lungs.
The lung nodules were digested with collagenase and
implanted subcutaneously on back of wild type BALB/
c mice. After 30 days, metastatic tumor nodules were
observed in the lungs and subsequently isolated and
cloned. The resulting metastatic cell line was named
TUBO-P2J. TUBO-P2J and TUBO cell lines displayed
a different morphology. As shown in Figure 1A, iso-
lated TUBO-P2J cells exhibited a more fibroblastic-like
phenotype than TUBO cells. To rule out the possibility
that TUBO-P2J originated from FVB/N-Tg/MMTV-neu,
MHC class I was expression was examined. TUBO-P2J
cells only expressed H-2Kd and not H-2Kq (Figure 1B).
These data suggest that TUBO-P2J is a metastatic version
of the TUBO cell line.
TUBO is a neu-dependent cell line that it is inhibited
in vivo by anti-neu antibody therapy [8]. Because
TUBO-P2J arose after anti-neu antibody treatment, we

























































































































Figure 1 Expression pattern of surface antigen and differential susceptibility to anti-neu antibody in TUBO and TUBO-P2J cell line. A)
Microscopic images of TUBO and TUBO-P2J cells. B) Differential expression of MHC class I molecule, H-2Dd expression of TUBO and TUBO-P2J
cells analyzed by flow cytometry is shown (left histogram). Representative analysis of H-2Kq and H-2Kd expression intensity in TUBO-P2J cells is
shown (right histogram). The isotype control is represented by the gray shaded region and MHC class I molecule expression is represented by
the black line. Data shown in each panel are representative of three independent experiments. C, D) Rat Neu protein expression of TUBO and
TUBO-P2J cells were evaluated with flow cytometry for surface expression (C) and western blot for total protein level (D) using purified ascites of
7.16.4 and PE- or HRP-conjugated anti-mIgG. E) Inhibition of cell viability by treatment with anti-neu antibody (left graph). Cells were treated with
anti-neu antibody (clone 7.16.4) and then cell viability was measured using the Premix WST-1 cell proliferation assay system. The assay was per-
formed in quadruplicate with essentially similar results. Cell viability was recorded as the optical density at 440 to 600 nm relative to that of the
sample not treated (mean ± SD). F) Therapeutic effects of anti-neu antibody on TUBO (left) or TUBO-P2J (right) bearing mice. WT BALB/c mice
(n = 4-6/group) were inoculated s.c. with 4 × 105 TUBO cells or 2 × 105 TUBO-P2J cells and treated i.p. with 200 μg anti-neu (α-neu) antibody or
isotype control (Ctrl) on day 12 and 100 μg antibody at 7 days after first treat. The growth of tumor measured once or twice a week. Data shown
in each panel are representative of two independent experiments.
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the neu protein was not observed by flow cytometry
(Figure 1C), and Western blot analysis revealed that
total neu protein levels were markedly reduced (Figure 1D).
To further evaluate if this alteration affected the susceptibil-
ity of TUBO-P2J to antibody therapy, we tested if anti-neuantibody was able to inhibit the growth of TUBO-P2J
in vitro and in vivo. As expected, anti-neu therapy inhibited
the growth of TUBO both in vitro and in vivo. However,
the ability of anti-neu therapy to inhibit TUBO-P2J in vitro
was significantly decreased (Figure 1E). In addition, anti-
neu therapy was unable to inhibit the growth of TUBO-P2J
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TUBO-P2J is an anti-neu resistant cell line that has meta-
static potential.
We also evaluated the susceptibility of TUBO and
TUBO-P2J to 12 chemotherapeutics that are commonly
used to treat breast cancer patients (Table 2). The IC50
for cisplatin, etoposide and irinotecan in TUBO-P2J
were similar or lower than that of TUBO. However, the
IC50 for the other 9 drugs was at least 5 times greater.
These data suggest that TUBO-P2J is also more resistant
to chemotherapy than the parental TUBO cell line.
TUBO-P2J spontaneously metastasizes to the lung and
displays increased migration and invasion activity
To determine the metastatic capacity of TUBO-P2J,
either TUBO or TUBO-P2J cells were injected subcuta-
neously into WT mice, and on day 14 the established
tumors were surgically resected. By day 40, all mice that
had been inoculated with TUBO-P2J died; however, mice
that had been inoculated with TUBO bearing survived for
100 days (Figure 2A). These data suggest that TUBO-P2J
metastases occur by day 14. To confirm this, we used small
animal PET-CT to detect metastatic lung masses. Mice in-
oculated with TUBO-P2J had detectable lung nodules
around day 28 after implantation (Additional file 1:
Figure S1). In addition, multiple lung nodules were
visually evident in mice inoculated with TUBO-P2J
around day 30 (Figure 2B). Thus, these data suggest that
TUBO-P2J cells maintain their metastatic capacity in vivo.
In order to study the intrinsic characteristics driving
metastasis of TUBO-P2J, we first evaluated the migra-
tion activity of TUBO and TUBO-P2J using scratch
wound assay and trans-well migration experiments.
First, 1x106 TUBO and TUBO-P2J cells were seeded
separately in 6-well plates. Twelve hours after plating,Table 2 Chemo susceptibility of TUBO and TUBO-P2J cells
Chemoreagent IC50
TUBO TUBO-P2J
Carboplatin 0.22 mg/ml 4.97 mg/ml
Cisplatin 4.2 ug/ml 3.53 ug/ml
Cyclophosphamide 0.15 mg/ml 1.93 mg/ml
Daunorubicin UD 326 ng/ml
Doxoruibicin 56.9 ng/ml 306.6 ng/ml
Epirubicin 2.87 ng/ml 40.3 ng/ml
Etoposide 84 ug/ml 76.63 ug/ml
Gemcitabin 0.55 ng/ml 6.4 ng/ml
Idarubicin UD 0.98 ug/ml
Irinotecan 1.7 mg/ml 0.95 mg/ml
Oxaliplatin 0.26 ug/ml 34.55 ug/ml
Vinorelbine 0.23 ug/ml 6.8 ug/ml
UD under detected.the bottom of each well was scratched with a pipette tip
to remove cells and create a “wound”. Within three days,
TUBO-P2J cells had migrated and covered much of the
exposed plate whereas very little migration was observed
in the wells containing TUBO cells (Figure 2C). To fur-
ther this analysis, we conducted trans-well migration
experiments. To this end, 1 × 105 TUBO or TUBO-P2J
cells were seeded in the upper chamber, and cell num-
bers in lower chamber were evaluated 4 hours later. The
migration capacity of TUBO-P2J was almost 20 times
greater than that of TUBO (P < 0.001) (Figure 2D).
Next, in an effort to determine if these differences pro-
moted the metastatic potential of TUBO-P2J cells, the
invasion ability of TUBO and TUBO-P2J cells was com-
pared with a matrigel coated trans-well insert. After a
three-day incubation period, a significantly greater num-
ber of TUBO-P2J had invaded the matrigel compared to
the parental TUBO cells (P < 0.05) (Figure 2E). Expres-
sion and enzyme activity of various matrix metallopro-
teases (MMPs) is associated with cell invasion. RT-PCR
analysis revealed that mRNA for MMP3, 9, 10 and 11
were increased in TUBO-P2J (Figure 2F). In addition,
gelatin zymopgraphy revealed that MMP9 present in
TUBO-P2J cells exhibited increased enzymatic activity
(Figure 2G). To test whether the active MMP9 expres-
sion caused increase of migration and invasion, MMP9
inhibitor I (CAS 1177749-58-4) was used. Invasion of
TUBO-P2J cells was reduced to more than 95% by 5 nM
of MMP9 inhibitor I (IC50 for MMP9) and blocked com-
pletely by 50 nM (Figure 2H). However, migration of
TUBO-P2J cells was not changed by MMP9 inhibitor
(Additional file 2: Figure S2). Collectively, these data
demonstrate that TUBO-P2J has acquired increased in-
vasive capabilities over TUBO, and that these character-
istics may be due to increased MMP9 activity.
TUBO-P2J displays characteristics of a transition from
epithelial to mesenchymal (EMT) cells
To determine the potential molecular changes driving
metastatic transition of TUBO cells, we conducted a
cDNA array between TUBO and TUBO-P2J (Additional
file 3: Figure S3). The expression of hundreds of genes
was increased or decreased in TUBO-P2J cells compared
to the parental TUBO cells. As a result, the gene expres-
sion profile of TUBO-P2J resembled that of the spontan-
eous metastatic breast carcinoma cell line 4T1. Among
the differences, the most prominent changes in TUBO-P2J
were loss of E-cadherin expression and gain of Fibronectin
and Vimentin expression. Generally, loss of E-cadherin is a
hallmark of epithelial-mesenchymal transition (EMT). To
confirm whether the metastatic capability of TUBO-P2J
cells was associated with acquisition of mesenchymal char-
acteristics, expression of known EMT genes was evaluated
with RT-PCR (Figure 3A). E-cadherin was expressed in
TUBO (n=3)
TUBO-P2J (n=3)











































































































Figure 2 (See legend on next page.)
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Figure 2 Metastatic capacity of TUBO-P2J cells in vitro and in vivo. A) Percent survival of TUBO and TUBO-P2J bearing mice. TUBO (4 × 105 /mice)
and TUBO-P2J (2 × 105 /mice) cells were implanted subcutaneously on the backs of mice. Fourteen days after implantation, primary tumors
were surgically removed and mouse survival was recorded. B) Picture of lungs from TUBO-P2J (2 × 104 /mice) tumor bearing mouse 30 days
after implantation. C) Scratch wound assay: 1 × 106 cells of TUBO or TUBO-P2J were seeded in 6 well culture plates. The surface of the culture
plates was scratched mechanically with pipette tips and cell migration was evaluated 3 days later. D) Trans-well migration assay: 5 × 104 cells
of TUBO and TUBO-P2J cells were added to the top plate and incubated for 4 hours. Migrated cells were counted from 5 randomly selected
fields under × 40 magnification and averages were calculated. Data shown are representative of three independent experiments (mean ± SD).
E) Invasion assay: 1 × 105cells of TUBO and TUBO-P2J cells were added to matrigel coated trans-well plates and incubated for 3 days. Invaded
cells were counted from 5 randomly selected fields under × 40 magnification and averages were calculated. Data shown are representative of
three independent experiments (mean ± SD). F) RT-PCR for expression of MMPs. G) Zymography for MMPs H) Inhibition of invasion by MMP9
inhibitor I. Invasion assay was done with indicated doses of MMP9 inhibitor by the same procedure as (E). Data shown are representative of two
independent experiments (mean ± SD). * is p < 0.05 and *** is p < 0.001 versus TUBO or DMSO.
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makers such as α-catenin, γ-catenin, Claudin1, Occludin1,
and Cytokeratin18 were expressed in TUBO-P2J, but at sig-
nificantly decreased levels from those observed in the par-
ental TUBO line. In contrast, the mesenchymal makers
(Fibronectin, Sm-actin, Vimentin, S100A4, and DDR2) and
















































Figure 3 Analysis of EMT profiles in TUBO-P2J cells. A) Measurement o
gene expression regulators by RT-PCR. B) Quantitative real-time PCR of EMT
and TUBO-P2J cells.mesenchymal cells were significantly increased in TUBO-
P2J (Figure 3A). Additionally, quantitative PCR (qRT-PCR)
of TUBO or TUBO-P2J cells revealed that TUBO-P2J cells
displayed characteristics of mesenchymal cells while
TUBO cells maintained more epithelial characteristics
(Figure 3B). To determine if these differences were also







































f mRNA expression of epithelial and mesenchymal markers and EMT
related genes(mean ± SD). C) EMT related protein expression of TUBO
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sion was reduced in TUBO-P2J cells. However, mesen-
chymal cell proteins such as vimentin, Snail, and
Twist1, were markedly enhanced in TUBO-P2J cells.
These data suggest that the EMT process might be re-
lated in phenotype changes of TUBO cells to TUBO-
P2J cells.
Intratumoral HER2 heterogeneity impacts the efficacy of
anti-HER2/neu therapy
Breast cancer patients express different levels of surface
HER2/neu, and are characterized as being either +1 to +3
by immunohistochemistry (IHC) [2]. However, even in +3
tumors not every cell positive for HER2/neu [11]. Thus,
there is intratumoral heterogeneity within human breast
cancer tumors, and this may often include highly meta-
static cells. Considering this fact, we took advantage








































Figure 4 Tumor heterogeneity impacts response to anti-neu antibody
mixture of 5 × 105 TUBO and TUBO-P2J cells. The percentage of TUBO-P2J
tumors for Neu. B-C) Mice were treated i.p. with 200 μg anti-neu (α-neu) a
and 19. Tumors were resected on day 21. The therapeutic effects of anti-ne
and overall survival (C). The sizes of tumor were measured twice a week. *P
experiments is shown.this end, we mixed TUBO cells with TUBO-P2J cells at
various ratios (1,000:1 or 10,000:1) prior to inoculation.
We then evaluated whether these mixed tumors showed
intratumoral heterogeneity and how these heterogeneic
tumors responded to anti-neu antibody treatment in a
neo-adjuvant setting (Figure 4). After transplanted tumors
were established (50-100 mm3), HER2/neu status of mixed
tumor was evaluated with IHC using rabbit anti-rNeu
antibody and HRP-conjugated anti-rabbit IgG. It is hard
to grade of IHC results because antigen and antibody are
not the same with that in human. But we grade IHC re-
sults based on guideline of HER2 testing in human breast
cancer [2]. IHC results showed that TUBO tumor is
HER2/neu positive (IHC 3+) because all the tumor cells
were stained completely on membrane and TUBO-P2J
tumor is HER2/neu negative (IHC 0-1+) because most
cells were not stained and even though some cells were












therapy. WT BALB/c mice (n = 6-8/group) were inoculated s.c. with a
cells was either 0.1% or 0.01%. A) Immunochemistry staining of mixed
ntibody or isotype control (Ctrl) on day 10, and 100 μg on day 13, 16,
u antibody were evaluated by measuring primary tumor growth (B)
< 0.05, ** P <0.01 and ***P < 0.001 versus control group. One of two
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tumor cells were positive in both mixed tumors, but the
staining intensity was moderate than TUBO tumors. The
percentages of positive cells were slightly higher in 0.1%
mixed tumor than 0.01%.
Tumor-bearing mice were treated with anti-neu anti-
body intraperitoneally 4 times at 3-day intervals. Three
days after the last anti-neu treatment, the primary tu-
mors were surgically removed. Prior to anti-neu therapy,
the growth of heterogeneic tumors was similar to that of
the homogenous TUBO inoculations; however, the efficacy
of anti-neu antibody therapy was diminished with addition
and increasing ratio of TUBO-P2J (Figure 4B & C).
Even though mixed tumors were not regressed like as
TUBO homogenous tumor, but anti-neu antibody ther-
apy significantly delayed tumor growth (p = 0.014) and
increased mouse survival (p < 0.001) when the hetero-
geneic ratio was 10,000:1 (0.001%). This effect was
abolished, however, when the ratio was 1,000:1 (0.01%).
At this ratio anti-neu antibody no longer suppressed
tumor growth and mouse survival was reduced. These
data support clinical observations that the percentage of
HER2/neu + within the tumor and IHC grades of tumors
correlate with response to anti-HER2/neu therapy, and
demonstrates that our heterogenous tumor model is useful
for future studies aimed at developing combination therap-
ies for low or equivocal HER2/neu + tumors.
Discussion
Even though trastuzumab provides clinical benefit to
breast cancer patients, resistance to trastuzumab de-
velops. About 70% of patients who initially respond to
trastuzumab eventually experience progression to meta-
static disease within a year [12] and only 11-26% of
Her2+ metastatic breast cancers respond to trastuzumab
monotherapy [13]. Therefore, understanding the mecha-
nisms for trastuzumab resistance and developing treat-
ment strategies for primary and acquired resistance are
important. In this study, we sought to define the mo-
lecular and functional changes driving loss of HER2/
neu expression and metastatic potential by examining
a spontaneously derived metastatic breast cancer cell
line, TUBO-P2J, with the parental HER2/neu positive
cell line, TUBO. In addition, we used this metastatic
variant to establish a clinically relevant intratumoral
HER2 heterogeneous tumor model to test anti-HER2/
neu antibody susceptibility. Using this model, we ob-
served that the clinical benefit of anti-neu antibody mono-
therapy correlated with heterogeneity of HER2/neu.
TUBO is rNeu positive, and highly susceptible to anti-
HER2/neu antibody therapy (clone 7.16.4) in vitro and
in vivo [8]. Unlike TUBO, rNeu expression inTUBO-P2J
is significantly reduced and cell surface levels were un-
detectable by flow cytometry. The loss of rNeu expressionalso rendered TUBO-P2J unresponsive to anti-neu anti-
body in vitro and in vivo. These results were similar to pre-
vious reports that neu-specific immunotherapy, including
anti-neu antibody and vaccines, induced antigen loss vari-
ants in FVB/N-TgN and FVB/N WT mice through immu-
noediting [14,15]. Antigen loss has also been observed in
patients treated with the therapeutic antibodies, trastuzu-
mab and rituximab [16,17]. Taking these reports and our
results together suggest that immunoediting might be a
one of mechanisms promoting resistance to antibody-based
treatments.
The metastatic process consists of a series of steps
including: migration, invasion, intravasation, arrest, extrava-
sation, and colonization; all of which must be successfully
completed in order to give rise to a metastatic tumor
[18-20]. TUBO cells are only capable of colonizing the lung
after intravenous injection [21]. TUBO-P2J cells, however,
successfully established lung metastatic nodules when im-
planted subcutaneously on the back of mice, and these
metastases arose within 14 days after implantation. These
data suggest that TUBO cells have a limitation in the me-
tastasis steps before intravasation, perhaps migration or
invasion. Our data revealed thatTUBO-P2J has signifi-
cantly increased migration and invasion activity over the
parental TUBO cell line. Knutson et al [14,15] suggested
that immunoediting could induce antigen negative vari-
ants through epithelial-mesenchymal transition (EMT).
The EMT process is characterized by the loss of epithelial
markers and gain of mesenchymal markers [22]. Gener-
ally, loss of E-cadherin is a hallmark of EMT. TUBO cells
expressed E-cadherin, but TUBO-P2J cells did not. Except
for the loss of N-cadherin expression, the gene expression
profile of TUBO-P2J represented EMT. Most notably was
the increased expression of the mesenchymal cell markers
DDR2, Snail 1, fibronectin, Sm-actin, Twist, and FOXC2,
and the reduced expression of the epithelial cell markers
Cytokeratin, Claudin, and Occludin. Thus, TUBO-P2J
might be another example for EMT and anti-HER2/neu
resistance induced by immunoediting. EMTalso correlates
with drug resistance [23]. Mice inoculated with TUBO-P2J
were less sensitive to both anti-neu therapy and chemo-
therapeutic drugs. The IC50 for 9 of 12 chemo drugs was
increased 5-130 times for TUBO-P2J (Table 2).
Intratumoral HER2 heterogeneity also exists [1,11,24].
Thus, one of clinical feature of resistance to trastuzumab
might be intratumoral HER2 heterogeneity. Using TUBO-
P2J, we developed a heterogenous tumor model through
implantation of mixtures of TUBO and TUBO-P2J. We ex-
pected that HER2/neu status should be 3+ when the ratio
of TUBO cells in mixture was higher than 99%. However
the IHC status of both 0.1% and 0.01% mixed tumor is 2+
or equivocal. The percentages of HER2/neu positive cells
were lower than expected. In addition, intensity of HER2/
neu positive cells in mixed tumors was weak than that of
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cells than expected can be explained with differences of cell
proliferation rates in in vitro and in vivo. However, it is hard
to understand why the intensity of HER2/neu positive cells
in mixed tumors is weak. It is not clear but might be caused
by cellular interaction between TUBO and TUBO-P2J.
In previous studies, we reported that anti-neu anti-
body can induce anti-tumor CD8+ and CD4+ T cell re-
sponses [8,25]. Because TUBO and TUBO-P2J share
many antigens, we hypothesized that if anti-neu anti-
body was able to target a majority of the tumor cells, it
would still reduce tumor burden. Mice inoculated with
tumors consisting of 0.01% TUBO-P2J responded to
anti-neu therapy and displayed increased survival.
However, when the percentage of TUBO-P2J was in-
creased to 0.1%, anti-neu therapy no longer provided
benefit on tumor mass and survival. In these experi-
ments, tumor bearing mice were treated in a neo-
adjuvant setting, which raises the possibility that a
single targeting treatment can select non-targeted cells
and can lose efficacy over time.
In conclusion, we isolated a spontaneous metastatic
breast cancer cell line, TUBO-P2J. This cell line dis-
played markers of EMT, and exhibited an increased
metastatic capacity compare to parental TUBO cells.
Furthermore, using this cell line we developed a mixed
tumor model to mimic clinical tumor heterogeneity
and low HER2/neu + tumor. Overall, this study emphasizes
the importance of combination therapy targeting multiple
antigens or oncogenic mechanisms, and provides a means
to test these therapies with more clinical relevancy.
Conclusion
This study describes a novel model of intratumoral
heterogenous metastatic breast cancer in immune compe-
tent mice that can be used to develop novel or combined
immunotherapies to overcome antibody resistance.
Additional files
Additional file 1: Figure S1. PET-CT imaging of TUBO-P2J bearing
mice. 2 × 104 cells of TUBO-P2J were injected subcutaneously into the
lower back of mice. Lung metastases were evaluated with small animal
PET-CT after intra-peritoneal injection of [18 F]. Images represent PET-CT
at days 7 days, 14 and 28.
Additional file 2: Figure S2. Migration and Invasion assay with MMP9
inhibitor. 5 × 104 (for migration) or 1 × 105 (for invasion) of TUBO-P2J
cells were added to the top plate with or without matrigel coating and
incubated for 4 hours (for migration) or 3 days (for invasion). Cells in the
bottom compartment were fixed and stained with H&E.
Additional file 3: Figure S3. Hierarchical clustering for the differentially
expressed genes between TUBO, TUBO-P2J, and 4T1 cell lines. Relative
gene expression levels of TUBO-P2J and 4T1 compare to that of TUBO
cell are showed as colored bars representing expression levels for a given
gene from cDNA array, aligned in a row and each cell is a different col-
umn. Red indicates increased expression, black is unchanged and green
is reduced, all relative to a control sample.Abbreviations
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